CVKD: Designing phase 3 trial for CAD-1005 in HIT
- Posted on May 8, 2026
- By Bing News
- 0 Views
- 1 min read
CVKD: Designing phase 3 trial for CAD-1005 in HIT
By David Bautz, PhD NASDAQ: CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Planning for Phase 3 Registration Trial of CAD-1005 in HIT On April 30, 2026, Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) announced an ‘End-of-Phase 2’ meeting with the U.S. Food and Drug Administration (FDA) in which the agency provided critical guidance on the company’s upcoming Phase 3 pivotal trial for CAD-1005 for the treatment of heparin-induced...
